Simon Laban

24PUBLICATIONS
74CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Tumour immunologyPredictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Mortality
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (24)

|Jun 19, 2026
Author Correction: MAGE-A4/MAGE-A8-targeted TCR-based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trial.

|May 31, 2026
MAGE-A4/MAGE-A8-targeted TCR-based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trial.

|Oct 16, 2025
Co-Stimulatory and Immune Checkpoint Molecule Expression on Peripheral Immune Cells Differs Age Dependently Between Healthy Donors and Patients with Head and Neck Squamous Cell Carcinoma.

Lisa K Puntigam, Ayla Grages, Julius M Vahl

|Sep 08, 2025
Randomized clinical efficacy and safety study of peltopepimut-S plus cemiplimab compared to cemiplimab alone in patients with recurrent/metastatic HPV16-positive head and neck cancer.

Caroline Even, Kevin J Harrington, Erminia Massarelli

|Jan 10, 2025
Identification of B Cell Subpopulations with Pro- and Anti-Tumorigenic Properties in an Immunocompetent Mouse Model of Head and Neck Squamous Cell Carcinoma.

Michael Sonntag, Sandra Stanojevic, Simon Laban

|Feb 08, 2024
INHBA is Enriched in HPV-negative Oropharyngeal Squamous Cell Carcinoma and Promotes Cancer Progression.

Tsima Abou Kors, Linda Hofmann, Annika Betzler

Pageof 4

Frequent Collaborators

14 joint publications

Cornelia Brunner

12 joint publications

Patrick J Schuler

6 joint publications

Adrian von Witzleben

5 joint publications

Johannes Doescher